NCT04990284已完成4 期
A Randomized, Parallel Group, Multicentre, Multinational, Prospective, Open-label Exploratory Study to Evaluate the add-on Effect of Opicapone 50 mg or Levodopa 100 mg as First Strategy for the Treatment of Wearing-off in Patients With Parkinson's Disease.
Bial - Portela C S.A.25 个研究点 分布在 5 个国家目标入组 106 人开始时间: 2021年11月29日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 106
- 试验地点
- 25
- 主要终点
- Change in Absolute OFF-time from baseline to end of study
研究概览
简要总结
This is a randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study in Parkinson's disease (PD) patients to evaluate the add-on efficacy of opicapone 50 mg or an extra dose of levodopa (L-DOPA) 100 mg as first strategy for the treatment of wearing-off.
详细描述
The study consists of a one-week screening period, four weeks of open-label treatment and two weeks of post-study follow-up. The total study duration for each patient will be approximately 7 weeks
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to comprehend and willing to sign an informed consent form and to comply with all aspects of the study.
- •Male or female patients aged 30 years or older.
- •Diagnosed with idiopathic PD according to the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria (2006) or according to the Movement Disorder Society (MDS) Clinical Diagnostic Criteria (2015).
- •Disease severity Stages I-III (Hoehn & Yahr staging) at ON.
- •Treated on a stable regimen for at least four weeks before screening with immediate-release L-DOPA/DDCI, three to four intakes per day, and up to maximum daily dose of 600 mg L-DOPA.
- •In case of any other anti-PD-treatments, they should be on a stable regimen for at least four weeks before screening, and not likely to need any adjustment during the study.
- •Signs of wearing-off phenomenon with average total daily OFF-time while awake of at least 1 hour, including the early morning pre-first dose OFF (i.e. the time between wake-up and response to the first L DOPA/DDCI dosage), despite optimal anti-PD therapy (based on Investigator's assessment).
- •Experiencing wearing-off phenomenon for at least 4 weeks but less than 2 years prior to screening.
- •For females: Postmenopausal for at least 2 years before screening, surgically sterile for at least 6 months before screening, or practicing effective contraception until the post-study visit. Female patients who request to continue with oral contraceptives must be willing to use non-hormonal methods of contraception in addition during the course of this study.
- •Have filled-in self-rating diary charts in accordance with the diary chart instructions and with ≤3 errors per day while awake, in the three consecutive days preceding randomization.
- •With at least 1 hour at OFF state per day, including the early morning pre-first dose OFF period (i.e. the time between wake-up and response to the first L DOPA/DDCI dosage), as recorded in at least two of the three-day self-rating diary charts for the three days preceding randomization.
- •Adequate compliance to relevant concomitant medication during the period between V1 and V2 (based on the Investigator's judgment).
排除标准
- •Non-idiopathic PD (atypical parkinsonism, secondary [acquired or symptomatic] parkinsonism, Parkinson-plus syndrome).
- •Severe and/or unpredictable OFF periods, according to Investigator's judgment.
- •Average total daily OFF-time while awake of >5 hours, including the early morning pre-first dose OFF, despite optimal anti-PD therapy (based on Investigator's assessment).
- •Treatment with prohibited medication: entacapone, tolcapone, monoamine oxidase (MAO) inhibitors (except selegiline up to 10 mg/day in oral formulation or 1.25 mg/day in buccal absorption formulation, rasagiline up to 1 mg/day or safinamide up to 100 mg/day), apomorphine or antiemetics with antidopaminergic action (except domperidone) within the last 4 weeks before screening.
- •Previous or planned (during the entire study duration) deep brain stimulation or stereotactic surgery (e.g. pallidotomy, thalamotomy).
- •Previous or current use of opicapone or L-DOPA/carbidopa intestinal gel infusion.
- •Use of any other investigational product (IP), currently or within the 3 months (or within 5 half-lives of the IP, whichever is longer) before screening.
- •Past (within the past year) or present history of suicidal ideation or suicide attempts.
- •Current or previous (within the past year) alcohol or substance abuse excluding caffeine or nicotine.
- •Phaeochromocytoma, paraganglioma, or other catecholamine secreting neoplasms.
- •Known hypersensitivity to the excipients of IP (including lactose intolerance, galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption).
- •History of neuroleptic malignant syndrome or non-traumatic rhabdomyolysis.
- •History of severe hepatic impairment (Child-Pugh Class C).
- •Current or previous (within the past year) diagnosis of psychosis, severe major depression or other psychiatric disorders that, based on the Investigator's judgment, might place the patient at increased risk or interfere with assessments.
- •Any medical condition that might place the patient at increased risk or interfere with assessments.
- •For females: Pregnant or breastfeeding.
- •Employees of the Investigator, study centre, Sponsor, clinical research organisation and study consultants, when employees are directly involved in this study or other studies under the direction of this Investigator or study centre, and their family members.
- •Persons committed to an institution by virtue of an order issued either by the judicial or other authorities.
- •With an average total daily OFF-time while awake of >5 hours, including the early morning pre-first dose OFF period (i.e. the time between wake-up and response to the first L DOPA/DDCI dosage), as recorded in at least two of the three-day self-rating diary charts for the three days preceding randomization
研究组 & 干预措施
50 mg opicapone once-daily
Experimental
干预措施: Opicapone (Drug)
100 mg of L-DOPA
Experimental
干预措施: L-DOPA/DDCI (Drug)
结局指标
主要结局
Change in Absolute OFF-time from baseline to end of study
时间窗: up to 7 weeks
OFF = Time when medication has worn off and is no longer providing benefit with regard to mobility, slowness, and stiffness.
Proportion of patients with one hour or more reduction in Absolute OFF-time from baseline to end of study (OFF-time responders)
时间窗: up to 7 weeks
OFF = Time when medication has worn off and is no longer providing benefit with regard to mobility, slowness, and stiffness.
Change in Absolute ON-time from baseline to end of study
时间窗: up to 7 weeks
ON = Time when medication is providing benefit with regard to mobility, slowness, and stiffness.
Proportion of patients with one hour or more increase in Absolute ON-time from baseline to end of study (ON-time responders)
时间窗: up to 7 weeks
ON = Time when medication is providing benefit with regard to mobility, slowness, and stiffness.
Change in Percentage OFF-time between baseline and end of study
时间窗: up to 7 weeks
OFF = Time when medication has worn off and is no longer providing benefit with regard
Change in Percentage ON-time between baseline and end of study
时间窗: up to 7 weeks
ON = Time when medication is providing benefit with regard to mobility, slowness, and stiffness.
次要结局
未报告次要终点
研究者
研究点 (25)
Loading locations...
相似试验
已完成
4 期
Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)Type 2 DiabetesNCT01541956Novartis Pharmaceuticals3,091
已完成
4 期
a multicenter, open-labeled, randomized, parallel-group study comparing fluticasone propionate nasal spray and oral fexofenadine hydrochroride as early seasonal treatment for Japanese cedar pollinosisJapanese cedar pollinosisJPRN-UMIN000000575Department of Otorhinolaryngology, Head & Neck Surgery, Faculty of Medicine, University of Yamanashi120
进行中（未招募）
不适用
The purpose of this study is to investigate the efficacy and safety of the ibuprofen suspension, developed by Berlin-Chemie AG for oral administration (20 mg/ml and 40 mg/ml) compared to Nurofen® in reducing fever and pain in children at the age of 3-9 years old with uncomplicated acute otitis media.Acute otitis media (AOM) is an acute inflammatory disease involving the mucosa of the middle ear. AOM is one of the most frequent complications of upper respiratory tract infections in children. Treatment of AOM requires use of drugs with antipiretic, analgesic and antinflammatory action, as well as antibiotics.EUCTR2015-004077-32-Outside-EU/EEABerlin-Chemie AG135
进行中（未招募）
1 期
ET-02: Second line therapy for patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinomaEUCTR2017-002453-11-GBThe Christie NHS Foundation Trust102
尚未招募
不适用
Effect of Bivalirudin on Aortic Valve Intervention Outcomes.- patients undergoing TAVR via transfemoral access - aortic valve replacement- aortaklepvervangingNL-OMON27624The Medicines Company8 Sylvan WayParsippany, NJ07054620